Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | ARAF | P10398 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090740 | 0.85 | MAP2K2 (0.41) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL25635486 | 0.81 | KMT2A (0.57) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6888038 | 0.81 | ALOX5 (0.51) | GAAALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL13753892 | 0.81 | NOS2 (0.43) | BRAFHDAC1GAAALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL18151874 | 0.80 | GAA (0.60) | HDAC1GAAALDH1A1KDM4EMAPT | |
| SCHEMBL22097516 | 0.80 | MYC (0.40) | GAAALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL6890987 | 0.79 | BRAF (0.51) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30871249 | 0.79 | HDAC1 (0.52) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1558074 | 0.79 | MAPT (0.56) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| Ammonia Solution, Strong SCHEMBL2316519 | 0.79 | KDM4E (0.61) | GAAALDH1A1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | disclosed |
| CN-1770980-A | Pyrazoles and methods of making and using the same | BIOGEN IDEC INC (US) | 2006-05-10 | — | — | CN | disclosed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | BRAF 126/4885HDAC1 2096/4885HDAC3 1184/4885 |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | BRAF 553/4885HDAC1 2992/4885HDAC3 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.